Gerald Clarke | 10/04/2013
As part of our Future Pharma Series, we spoke to Dr. Stephen Minger, Chief Scientist, Research and Applied Markets at Life Sciences, GE Healthcare about the future of regenerative medicine. As he sits on the board of directors for the Centre for Commercialization of Regenerative Medicine, he also discusses how primary research can be translated into commercial success.
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More